Host Led Harm Reduction Approach Among Men Who Have Sex With Men Who Engaged in Chemsex in Bangkok, Thailand: A Pre-Implementation Study
Overview
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Institute of HIV Research and Innovation Foundation, Thailand
- Enrollment
- 76
- Locations
- 1
- Primary Endpoint
- Substance use-related harm assessed by self-administered questionnaire
Overview
Brief Summary
This study evaluates the pre-implementation phase of a host-led harm reduction model for men who have sex with men (MSM) engaging in chemsex in Bangkok, Thailand, focusing on understanding harms, contexts, and needs to develop a tailored intervention.
Detailed Description
HAMMOCK is a cross-sectional mixed-methods study designed to explore chemsex practices among MSM, including both hosts and guests, as well as key stakeholders such as CSOs, hospital staff, and police.
The study aims to:
- Explore substance-related, sexual health, mental health, and socio-legal harms
- Understand the context and dynamics of private chemsex parties
- Co-develop a novel host-led harm reduction model
- Identify barriers and facilitators to implementation The study includes both quantitative (self-administered questionnaires) and qualitative (in-depth interviews) components and follows a two-phase approach: exploration and preparation phases under the EPIS framework.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Other
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Male
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •MSM aged ≥18 years
- •Able to communicate in Thai
- •Specific by group:
- •Chemsex hosts: hosted ≥2 times in past 6 months
- •Chemsex guests: attended ≥2 times in past 6 months
- •CSO / hospital / police staff: working ≥3 months in related roles
- •Provide informed consent
Exclusion Criteria
- •Unable to provide informed consent (e.g., under substance influence at consent)
Arms & Interventions
Single Arm - Mixed-method Harm Reduction Model Development
Participants (chemsex party hosts, guests, CSO staff, hospital staff, and police officers) will participate in a mixed-method study consisting of two phases (Exploration and Preparation) to assess harms related to chemsex and to develop and refine a novel harm reduction model for private chemsex party settings.
Intervention: Self-administered questionnaire assessment (Behavioral)
Single Arm - Mixed-method Harm Reduction Model Development
Participants (chemsex party hosts, guests, CSO staff, hospital staff, and police officers) will participate in a mixed-method study consisting of two phases (Exploration and Preparation) to assess harms related to chemsex and to develop and refine a novel harm reduction model for private chemsex party settings.
Intervention: Semi-structured in-depth interviews (IDIs) (Behavioral)
Single Arm - Mixed-method Harm Reduction Model Development
Participants (chemsex party hosts, guests, CSO staff, hospital staff, and police officers) will participate in a mixed-method study consisting of two phases (Exploration and Preparation) to assess harms related to chemsex and to develop and refine a novel harm reduction model for private chemsex party settings.
Intervention: Development and refinement of harm reduction model (Behavioral)
Outcomes
Primary Outcomes
Substance use-related harm assessed by self-administered questionnaire
Time Frame: Baseline (during Exploration phase, prior to model development)
Substance-related harms will be assessed using a structured self-administered questionnaire. The assessment includes: * Patterns of substance use (snorting, injecting, ingesting, anal insertion) * Frequency of use * Physical harms (e.g., injection-related injuries, overdose) * Psychological harms (e.g., substance dependence) This is a descriptive assessment; no composite scale score is generated.
Sexual health risk behaviors assessed by self-administered questionnaire
Time Frame: Baseline (during Exploration phase, prior to model development)
Sexual health risks will be assessed using a structured questionnaire including: * Number of sexual partners * Condom use * HIV/STI testing history * Self-reported HIV status * Pre-exposure prophylaxis (PrEP) use and adherence * Antiretroviral therapy (ART) adherence among participants living with HIV This is a descriptive assessment; no composite scale score is generated.
Depression severity assessed by Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Baseline (during Exploration phase, prior to model development)
Depression will be assessed using the Patient Health Questionnaire-9 (PHQ-9): * Score range: 0 to 27 * Interpretation: * 0-4: Minimal depression * 5-9: Mild * 10-14: Moderate * 15-19: Moderately severe * 20-27: Severe Higher scores indicate worse depression severity
Anxiety severity assessed by Generalized Anxiety Disorder-7 (GAD-7)
Time Frame: Baseline (during Exploration phase, prior to model development)
Anxiety will be measured using the Generalized Anxiety Disorder-7 (GAD-7): * Score range: 0 to 21 * Interpretation: * 0-4: Minimal * 5-9: Mild * 10-14: Moderate * 15-21: Severe Higher scores indicate worse anxiety
Secondary Outcomes
- Perceived stigma and socio-legal harm assessed by structured questionnaire(Baseline (during Exploration phase, prior to model development))